Zero. For the first time in recorded history, not one woman aged 20 to 24 died from cervical cancer in England between 2020 and 2024. The figure stands out. It marks a stark departure from historical patterns. And it traces directly to a vaccination program launched in 2008.
Researchers at Queen Mary University of London examined population-based mortality data spanning 2001 to 2024. They matched it against HPV vaccination coverage records. The results, published in The Lancet, show a 100% reduction in cervical cancer deaths for that youngest age group. No deaths occurred. Historical trends predicted 23.1. The confidence interval runs from 84% to 100%. Such numbers command attention from oncologists, public health officials and policymakers alike.
Prof Peter Sasieni, professor of cancer epidemiology at Queen Mary University of London and lead author, put it plainly. “It’s incredible to think that a single jab can almost eliminate a particular type of cancer.” His team estimates the program has already prevented nearly 200 cervical cancer deaths in England. The precise figure from the study sits at 199.6, with a 95% confidence interval of 125.0 to 274.2. This isn’t projection. It’s observed impact drawn from official records.
The vaccine targets human papillomavirus. That virus causes 99% of cervical cancers. Introduced for girls aged 12 to 13 in 2008, with catch-up campaigns for older teens, the program achieved coverage rates of 88% to 90% in the key cohorts now entering their twenties. Coverage later slipped. Current national uptake for girls by age 15 hovers around 76%. In London it falls to 60%. Those drops worry experts. They could reverse hard-won gains.
But look at the data first. For women aged 20 to 24 in 2015-2019, mortality fell 80%. The interval reads 51% to 94%. Among 25- to 29-year-olds in 2020-2024 the reduction reached 69%. Vaccinated women in their early thirties saw a 63% lower relative risk of death. The pattern holds. Higher vaccination at ages 12 or 13 correlates with near-zero mortality before 30. Sasieni calls the current numbers the tip of the iceberg. As vaccinated generations age, thousands more deaths will be averted.
The BBC highlighted the study’s status as the first of its kind to examine mortality rather than incidence alone. Previous work documented sharp drops in cervical cancer cases and precancerous lesions. This analysis goes further. It quantifies lives saved. Cancer Research UK, which funded the work, described the findings as an incredible milestone. “We know the HPV vaccine is extremely effective at stopping cervical cancer before it starts and for the first time these findings show it is saving lives,” said Michelle Mitchell, the organization’s chief executive, in a statement carried by both the BBC and Cancer Research UK’s own news site.
The Guardian reported similar conclusions but added a cautionary note on falling uptake. Sasieni warned there. “The falling HPV vaccine uptake – now just 75% nationally and 60% in London – means that without swift and concerted efforts to increase HPV vaccine uptake, we could see a reversal of these trends. There could be another 15-25 avoidable deaths each year in young women and eventually about 200 deaths from cervical cancer each year that could be prevented if we can increase vaccine uptake to pre-Covid levels.”
Those words carry weight. Cervical cancer remains the fourth most common cancer in women globally. In England roughly 3,300 cases appear each year. The disease once carried a heavy toll among younger women. Routine screening helped reduce that burden over decades. Yet the vaccine’s arrival produced an acceleration no one fully anticipated. Coverage neared WHO targets before the pandemic disrupted delivery. Recovery has been uneven. Communities with lowest uptake face the greatest risk of resurgence.
Public health leaders have responded. The NHS rolled out catch-up campaigns through community pharmacies. Self-testing kits for cervical screening now reach women who skip appointments. Caroline Temmink, NHS Director of Vaccination, called the data “hugely encouraging.” She reminded a generation that cervical cancer and certain other HPV-related cancers need not pose a threat. The Department of Health and Social Care echoed the sentiment, citing the “extraordinary impact” while pledging further boosts to uptake.
Dr Alison Wright, president of the Royal College of Obstetricians and Gynaecologists, welcomed the “exciting and powerful data.” Fewer diagnoses and fewer deaths now appear realistic. Helen Hyndman, lead nurse at The Eve Appeal, struck a more urgent tone. Elimination targets once eyed for 2040 could slip to 2050 without faster progress on both vaccination and screening. “We need urgent action,” she said.
The vaccine’s reach extends beyond cervical cancer. It protects against cancers of the anus, penis, vagina, vulva, mouth and throat. Boys have received it since 2019, reducing transmission and their own risk. Yet the mortality data released this month focuses on female outcomes from the original girls-only program. The ecological study design carries limits. It relies on age-group aggregates rather than individual vaccination records. It assumes no herd immunity effect. Still, the size of the drop and the consistency across cohorts make confounding explanations difficult to sustain.
Similar patterns appear elsewhere. A U.S. analysis published earlier in 2026 by the American Cancer Society found cervical cancer incidence down 27% nationally in the vaccination era, with steeper declines in states boasting higher immunization rates. Al Jazeera covered the UK findings alongside international context, noting hopes for other countries now scaling up programs. Medical Xpress and The BMJ summarized the near-complete protection observed in vaccinated UK teens and called for equitable global access.
Back in England the numbers tell their own story. Zero deaths where 23 once seemed inevitable. Two hundred mothers, daughters, sisters and friends who remain alive. The achievement rests on a simple intervention delivered in schools. Its success now depends on sustaining and expanding that coverage. Mitchell put the stakes clearly. Targeted action must reach communities with the lowest uptake. Otherwise the trajectory could bend backward.
Prof Sasieni remains optimistic despite the warning. With sustained high coverage, he says, HPV vaccination together with screening could drive cervical cancer rates so low that almost no one develops the disease. The data support that view. They also show how quickly gains can erode when participation slips. Health systems face a choice. They can lock in these extraordinary reductions or watch them fade. The evidence, fresh from The Lancet this month, leaves little room for ambiguity.
WebProNews is an iEntry Publication